In addition to sharing technical results summaries on clinicaltrials.gov and eudract.ema.europa.eu (EudraCT), Amgen has committed to publicly disclose a synopsis of each clinical study report (CSR Synopsis) for Amgen-sponsored trials included in the marketing application beginning with new product approvals in 2015.

Synopses for clinical trials submitted in marketing applications for new Amgen products and indications in the US and EU since 2014 are posted within 90 days after regulatory approval in the region with the later approval. For subsequent marketing applications in other countries, synopses for additional studies conducted to support these approvals are posted after the respective approvals.

Synopses are also available for clinical trials in patients (and for selected non-interventional studies) back to 2004, for approved products and indications or for programs where development has discontinued.

The CSR synopses are redacted to remove commercially confidential or personally identifying patient information before posting on AmgenTrials.com.

This information is intended to satisfy public disclosure commitments and shall not be used for any other purpose. It shall also not be considered to be a claim for any marketed product. Some information in this document may differ from, or not be included in, the approved labeling for the product. Please refer to the full prescribing information for indications and proper use of the product.

To locate the CSR synopsis for a particular clinical trial, please click on the name of the product of interest below. You will be taken to a list of clinical trials by product from where you can select the particular clinical trial of interest by the study number and title. Please note the list of products will be visible as the CSR synopses are made available.

Product List

List of products alphabetized by generic name
  • ABP 215 : ABP 215
  • ABP 501 : ABP 501
  • ABP 710 : Infliximab
  • ABP 980 : ABP 980
  • AMG 009 : AMG 009
  • AMG 076 : AMG 076
  • AMG 102 : AMG 102
  • AMG 108 : AMG 108
  • AMG 139 : AMG 139
  • AMG 151 : AMG 151
  • AMG 167 : AMG 167
  • AMG 172 : AMG 172
  • AMG 181 : AMG 181
  • AMG 208 : AMG 208
  • AMG 220 : AMG 220
  • AMG 221 : AMG 221
  • AMG 223 : AMG 223
  • AMG 282 : AMG 282
  • AMG 317 : AMG 317
  • AMG 319 : AMG 319
  • AMG 333 : AMG 333
  • AMG 337 : AMG 337
  • AMG 357 : AMG 357
  • AMG 386 : AMG 386
  • AMG 401 : AMG 401
  • AMG 403 : AMG 403
  • AMG 423 : Omecamtiv Mecarbil
  • AMG 477 : AMG 477
  • AMG 479 : Ganitumab
  • AMG 487 : AMG 487
  • AMG 517 : AMG 517
  • AMG 557 : AMG 557
  • AMG 579 : AMG 579
  • AMG 581 : AMG 581
  • AMG 595 : AMG 595
  • AMG 623 : AMG 623
  • AMG 655 : Conatumumab
  • AMG 706 : Motesanib Diphosphate
  • AMG 745 : AMG 745
  • AMG 747 : AMG 747
  • AMG 761 : AMG 761
  • AMG 780 : AMG 780
  • AMG 801 : AMG 801
  • AMG 811 : AMG 811
  • AMG 820 : AMG 820
  • AMG 827 : brodalumab
  • AMG 837 : AMG 837
  • AMG 853 : AMG 853
  • AMG 853 : Vidupiprant
  • AMG 876 : AMG 876
  • AMG 951 : dulanermin
  • anakinra : anakinra
  • blinatumomab : BLINCYTO™
  • carfilzomib : Kyprolis™
  • Cinacalcet HCl : Sensipar®
  • darbepoetin alfa : Aranesp®
  • denosumab : Prolia®
  • denosumab : XGEVA®
  • Epoetin alfa : EPOGEN®
  • Erenumab : Aimovig™
  • Etanercept : Enbrel®
  • etelcalcetide : Parsabiv™
  • evolocumab : Repatha™
  • Palifermin : Palifermin
  • Panitumumab : Vectibix®
  • Pegfilgrastim : Neulasta®
  • r-metHuGDNF : Liatermin
  • romiplostim : Nplate®
  • Romosozumab : EVENITY®
  • talimogene laherparepvec : IMLYGIC™